Quantum Biopharma (QNTM) Total Non-Current Liabilities (2018 - 2026)

Quantum Biopharma has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $11.0 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $11.0 million, up 46.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.0 million (up 46.97% YoY), and the FY2025 annual result was $6.1 million, changed N/A from the prior year.
• Total Non-Current Liabilities came in at $11.0 million for Q1 2026 at Quantum Biopharma, up from $6.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $11.0 million in Q1 2026 to a low of -$522884.0 in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $1.9 million (2022), against an average of $3.1 million.
• Across the five-year window, Total Non-Current Liabilities sank 98.97% in 2022 and soared 4223.27% in 2024, its largest moves.
• Quantum Biopharma's Total Non-Current Liabilities stood at $38004.0 in 2022, then tumbled by 443.08% to -$130383.0 in 2023, then jumped by 2923.19% to $3.7 million in 2024, then soared by 64.58% to $6.1 million in 2025, then jumped by 82.03% to $11.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $11.0 million (Q1 2026), $6.1 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.